The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
Authors:
- Zhenhe SuoZSZhenhe Suo
- Gunnar B. KristensenGKGunnar B. Kristensen
- Mark BaekelandtMBMark Baekelandt
- Jahn M. NeslandJNJahn M. Nesland
- 1 July 2006
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (1) , 15-21
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Ephrin signaling in vivo: Look both waysDevelopmental Dynamics, 2004
- Expression and functional effects of Eph receptor tyrosine kinase A family members on Langerhans like dendritic cellsBMC Immunology, 2004
- Inhibition of Tumor Growth and Angiogenesis by Soluble EphB4Neoplasia, 2004
- Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signalingNature Neuroscience, 2004
- Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancerGynecologic Oncology, 2004
- CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient SurvivalThe American Journal of Pathology, 2002
- The protein tyrosine kinase family of the human genomeOncogene, 2000
- RTK mutations and human syndromesTrends in Genetics, 2000
- Eph Receptors and Ligands Comprise Two Major Specificity Subclasses and Are Reciprocally Compartmentalized during EmbryogenesisNeuron, 1996
- eph, the largest known family of putative growth factor receptorsBritish Journal of Cancer, 1994